Sanofi (SNY)

Oncology Corporate Profile

Stock Performance

43.6200
-0.4200

3 Month Stock History Chart

HQ Location

55 Corporate Drive
Bridgewater, NJ 8807

Company Description

Sanofi engages in the research, development, manufacture, and marketing of healthcare products worldwide. It offers products in various therapeutic fields, including cardiovascular, thrombosis, oncology, metabolic disorders, central nervous system, and internal medicine and vaccines.

Website: http://en.sanofi.com/

Brand Generic Indication
Campath®alemtuzumabCampath® is a CD52-directed cytolytic antibody indicated as a single agent for the treatment of B-cell chronic lymphocytic leukemia.
Clolar®clofarabineClolar® is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens. This use is based on the induction of complete responses. Randomized trials demonstrating increased survival or other clinical benefit have not been conducted.
Elitek®rasburicaseElitek® is indicated for the initial management of plasma uric acid levels in pediatric patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid.
Eloxatin®oxaliplatinEloxatin®, used in combination with infusional 5-FU/LV, is indicated for adjuvant treatment of stage III colon cancer patients who have undergone complete resection of the primary tumor. The indication is based on an improvement in disease-free survival, with no demonstrated benefit in overall survival after a median follow up of 4 years. Eloxatin®, used in combination with infusional 5-FU/LV, is indicated for the treatment of advanced carcinoma of the colon or rectum.
Jevtana®cabazitaxelJevtana® is a microtubule inhibitor indicated in combination with prednisone for treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel containing treatment regimen.
Taxotere®docetaxelTaxotere® is a microtubule inhibitor used for:

Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC.

Non-Small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC

Hormone Refractory Prostate Cancer (HRPC): with prednisone in androgen independent (hormone refractory) metastatic prostate cancer

Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction

Squamous Cell Carcinoma of the Head and Neck Cancer (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN.
Thyrogen®thyrotropin alfaThyrogen® (thyrotropin alfa for injection) is indicated for use as an adjunctive diagnostic tool for serum thyroglobulin (Tg) testing with or without radioiodine imaging in the follow-up of patients with well-differentiated thyroid cancer. Thyrogen (thyrotropin alfa for injection) is indicated for use as an adjunctive treatment for radioiodine ablation of thyroid tissue remnants in patients who have undergone a neartotal or total thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of metastatic thyroid cancer.
Zaltrap®afliberceptZaltrap®, in combination with 5-fluorouracil, leucovorin, irinotecan-(FOLFIRI), is indicated for patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed following an oxaliplatin-containing regimen.

View additional information on commercial products here »

  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
larotaxel / XRP9881taxane (semi-synthetic)Bladder cancerIII
alvocidib / HMR1275cyclin-dependent kinase inhibitorChronic Lymphocytic Leukemia (CLL)III
S-1fluoropyrimidine (oral)Colorectal cancerIII
S-1fluoropyrimidine (oral)Gastric cancerIII
SAR302503 (TG101348)JAK2 inhibitorMyelofibrosisIII
xaliproden / SR57746neurotrophicPeripheral sensory neuropathiesIII
isatuximabAnti-CD38 naked mAbRelapsed refractory multiple myelomaIII
ombrabulin / AVE8062vascular disrupting agentSarcomaIII
Campath® / alemtuzumabanti-CD52 monoclonal antibody2nd line metastatic Chronic Lymphocytic Leukemia (CLL)III
Clolarp® / clofarabineantimetaboliteAcute Myelogenous Leukemia (AML)III
Jevtana® / cabazitaxel / XRP6258taxane1st line metastatic hormone-refractory Prostate cancer (HRPC)III
Taxoterep® / docetaxeltaxanePediatric cancerIII
Zaltrap® / aflibercept / VEGF TrapVEGF-A inhibitor1st line metastatic hormone-refractory Prostate cancer (HRPC)IIIRegeneron
Zaltrap® / aflibercept / VEGF TrapVEGF-A inhibitor2nd line metastatic Non Small Cell Lung Cancer (NSCLC)IIIRegeneron
larotaxel / XRP9881taxane1st line metastatic Breast cancerII
larotaxel / XRP9881taxaneAdjuvant Breast cancerII
SAR439684PD-1 inhibitorAdvanced cutaneous squamous cell carcinoma (CSCC)II
SAR3419anti-CD19 monoclonal antibody (maytansin-loaded)B-cell Acute Lymphocytic Leukemia (B-ALL)IIImmunogen
tasidotinanalog of dolastatin 15MelanomaIIErgomed Group
thymoglobulinimmunosuppressiveMyelodysplastic Syndrome (MDS)II
Clolar® / clofarabineantimetaboliteMyelodysplastic Syndrome (MDS)II
Zaltrap® / aflibercept / VEGF TrapVEGF-A inhibitor1st line metastatic Colorectal cancerIIRegeneron
AVE9633anti-CD33 monoclonal antibody (maytansin-loaded)Acute Myelogenous Leukemia (AML)I
SAR103168multiple tyrosine kinase inhibitorAcute Myelogenous Leukemia (AML)I
XL765PI3K and mTOR inhibitorGlioblastoma Multiforme (GBM)IExelixis
SAR566658anti-DS6 monoclonal antibody (maytansin-loaded)Various cancer typesI
SAR408701anti-CEACAM5 monoclonal antibody (maytansin-loaded)Various cancer typesI
SSR244738antitumoral agentVarious cancer typesI
SAR428926anti-Lamp1 monoclonal antibody (maytansin-loaded)Various cancer typesI
SSR97225antimitotic agentVarious cancer typesI
SAR650984anti-CD38 monoclonal antibody (naked)Various cancer typesIImmunogen
Mozobil® / plerixaforimmunostimulantAcute Myelogenous Leukemia (AML)I
Gene Signature TestdiagnosticsColorectal cancer genomic analysisDevelopment
Multiplex PredictivediagnosticsVarious cancer typesDevelopment

View additional information on product candidates here »

Source: http://en.sanofi.com/

Recent News Headlines

FDA Rejects Sanofi/Regeneron’s Sarilumab

10/31/2016 03:41 pm

(PharmaTimes [UK]) Oct 31, 2016 - US regulators are refusing to approve Sanofi and Regeneron's sarilumab to treat patients with rheumatoid arthritis until certain manufacturing issues are addressed.

Sanofi Gets $43 Mln U.S. Funding To Spur Zika Vaccine Development

9/27/2016 04:55 pm

(Business Insider/Reuters) Sept 26, 2016 - Sanofi SA said on Monday the U.S. Department of Health and Human Services approved $43.18 million in funding to accelerate the development of a Zika vaccine, as part of efforts to prevent the infection.

FDA Set To Decide On Two Likely Blockbuster Drugs By Sanofi Genzyme

9/26/2016 04:31 pm

(Boston Business Journal) Sept 26, 2016 - The second of two potential drugs for immune system disorders that are together expected to bring in peak annual revenues of between $3 billion and $7 billion to Sanofi Genzyme and a New York based partner in the next few years is expected to have a decision on U.S. approval by next spring.

UnitedHealth Trims Drug Coverage, Including Sanofi Insulin

9/23/2016 04:26 pm

(Reuters) Sept 22, 2016 - UnitedHealth Group (UNH.N), the largest U.S. health insurer, will stop covering several brand-name drugs as of next year, reinforcing a trend of payers steering prescriptions to lower-priced options.

Alphabet's Verily, Sanofi to Invest $500 Million in Diabetes

9/12/2016 05:09 pm

(Bloomberg Technology) Sept 12, 2016 - French drugmaker Sanofi and Alphabet Inc.'s life sciences arm plan to invest about $500 million in a joint venture to tackle diabetes amid forecasts for the number of people with the disease to surge.

Pfizer Trumps Sanofi With Medivation Deal for $14 Billion

8/22/2016 11:53 am

(Bloomberg) Aug 22, 2016 - Pfizer Inc. agreed to buy Medivation Inc. in a deal that values the company at about $14 billion and leaves French drugmaker Sanofi jilted.

Amgen, Sanofi Cholesterol Drugs Not Cost-Effective, Study Says

8/17/2016 04:26 pm

(Bloomberg) Aug 16, 2016 - Amgen Inc., Sanofi and Regeneron Pharmaceuticals Inc. would need to cut prices on their new cholesterol-lowering drugs by more than two-thirds to make them cost-effective to use in the U.S., a study found.

Sanofi Gains EU Approval for Boehringer Consumer Health Unit Buy

8/4/2016 04:19 pm

(Reuters) Aug 4, 2016 - French drugmaker Sanofi secured EU antitrust approval on Thursday for its proposed buy of German peer Boehringer Ingelheim's consumer health business after agreeing to divest businesses from both companies in nine EU countries.

Sanofi Sees Cure for Cancer Woes in Moving West for Acquisitions

7/12/2016 03:27 pm

(Bloomberg) July 12, 2016 - Sanofi is going west once more in its search for cancer gold. Chief Scientific Officer Gary Nabel says to revive its oncology business, Sanofi is hunting for assets ranging from approved cancer drugs to experimental ones that mine new expertise, such as exploiting flaws in tumor cells.

Sanofi Teams Up With U.S. Army on Zika Vaccine

7/6/2016 05:22 pm

(NASDAQ/Dow Jones Business News) July 6, 2016 - Sanofi SA has formed a partnership with the U.S. Army to expand research and development of an experimental Zika vaccine that has shown promise in early laboratory studies and is among a few candidates expected to be tested on humans in the coming months.

Medivation Agrees to Open Its Books to Sanofi

7/6/2016 05:05 pm

(Reuters) July 5, 2016 - U.S. cancer drug company Medivation Inc said on Tuesday it had agreed to provide confidential information to French pharmaceutical company Sanofi SA as part of exploring a sale that would be open to other bidders.

Sanofi Said to Consider Adding Future Payments to Medivation Bid

6/23/2016 04:33 pm

(Bloomberg) June 22, 2016 - Sanofi, the French drugmaker, is considering improving its $9.3 billion takeover offer for Medivation Inc. by committing to making future payments if the U.S. biotech company meets certain targets, according to people familiar with the matter.

Supreme Court’s Ruling In Patent Case A Blow To Drug Industry

6/20/2016 12:05 pm

(STAT) June 20, 2016 - The Supreme Court dealt a defeat to the pharmaceutical industry Monday in a closely watched patent law case that drug makers had argued endangered their continued investments in drug research and development.

Sanofi Hopes to Oust Medivation's Board By August 1

6/9/2016 04:32 pm

(Reuters) June 8, 2016 - Sanofi said on Wednesday it aims to remove the board of takeover target Medivation by Aug. 1 at the latest.

Medivation Pulls Up Shareholder Drawbridge as Sanofi Battle Looms

6/2/2016 04:58 pm

(TheStreet.com) June 2, 2016 - The cancer drug maker moves to lock new shareholders out of an upcoming vote.

Sanofi Wins FDA Panel’s Backing for Once-Daily Diabetes Combo

5/26/2016 05:02 pm

(Bloomberg) May 25, 2016 - Sanofi’s once-a-day shot for diabetes that combines two drugs should be approved for sale, a group of advisers to the U.S. Food and Drug Administration said.

QIAGEN Partners to Develop Predictive Tests in Oncology

5/26/2016 11:04 am

(QIAGEN) May 25, 2016 – An initial project will be to develop and market PITX2 as a marker to predict effectiveness of anthracycline treatment in triple negative and other high-risk breast cancer patients.

Sanofi Moves To Oust Medivation Board In $9.3 Bln Takeover Fight

5/25/2016 04:15 pm

(Reuters) May 25, 2016 - French drugmaker Sanofi named eight candidates to replace the entire board of Medivation on Wednesday, stepping up pressure on the U.S. cancer drug company which has rejected its $9.3 billion takeover approach.

Biden to Host National Cancer Research Summit in Washington

5/25/2016 11:01 am

(ABC News/Associated Press) May 24, 2016 - Vice President Joe Biden will bring together scientists, oncologists, donors and patients for a national conference on cancer research in Washington, the White House said Tuesday.

Celsion Announces Presentation of OVATION Study Clinical Trial Design at Upcoming ASCO 2016 Meeting

5/24/2016 11:01 am

(4-traders) May 24, 2016 - Celsion Corporation, an oncology drug development company, today provided an update on its ongoing OVATION study, a Phase Ib dose escalating clinical trial combining GEN-1, the Company's DNA-based immunotherapy, with the standard of care for the treatment of newly-diagnosed patients with advanced ovarian cancer who will undergo neoadjuvant chemotherapy followed by interval debulking surgery.

FDA Staff Question Usefulness Of Sanofi Diabetes Drugs

5/23/2016 05:13 pm

(Reuters) May 23, 2016 - A preliminary review by the U.S. Food and Drug Administration questioned the usefulness of a combination diabetes drug made by Sanofi SA's and said it was unclear whether one component, lixisenatide, contributed to its benefit.

A Treatment Vaccine for Low-Risk Prostate Cancer

5/20/2016 11:03 am

(Medscape Medical News) May 20, 2016 - A Louisiana-based biopharmaceutical company is betting that its experimental immunotherapeutic vaccine can keep previously untreated prostate cancer in check.

Sanofi Presses On with Threat to Oust Medivation's Board

5/13/2016 04:51 pm

(Reuters) May 13, 2016 - France's Sanofi SA was moving ahead on Friday with preparations to replace Medivation Inc's board of directors after the U.S. cancer drug maker refused to engage with it in sale talks based on a $9.3 billion acquisition offer.

HTG Molecular Diagnostics Announces Immuno-oncology Research Collaboration Agreement with Bristol-Myers Squibb

5/13/2016 11:04 am

(NASDAQ) May 12, 2016 - HTG Molecular Diagnostics, Inc., a provider of instruments and reagents for molecular profiling applications, today announced a research collaboration agreement with Bristol-Myers Squibb to evaluate the potential for immuno-oncology molecular profiling in multiple tumor types.

Ex-FDA Head and Sanofi Call for Harmonized Drug Regulation

5/12/2016 05:31 pm

(Reuters) May 11, 2016 - Drug regulation has failed to keep up with a globalized world and governments should harmonize oversight to improve patients' access to new and innovative medicines.

Sanofi, Amgen Cholesterol Drugs Win UK Backing After Price Cuts

5/6/2016 05:12 pm

(Reuters) May 5, 2016 - Two rival cholesterol-lowering injections from Sanofi and Amgen have been recommended by Britain's healthcare cost watchdog after the manufacturers offered special discounts to the country's state-run health service.

Sanofi Ready to Up Offer for Drugmaker Medivation, Could Oust Board

5/6/2016 04:36 pm

(Reuters) May 5, 2016 - France's Sanofi said it could raise its proposed $9.3 billion deal to buy Medivation if the U.S. cancer drugmaker engaged in talks, threatening to go directly to shareholders to oust the board if not.

Sanofi Says It Will Try to Oust Medivation Board Members if Deal Talks Don’t Start

5/6/2016 11:59 am

(Wall Street Journal) May 5, 2016 - Sanofi SA on Thursday said it sent a letter to Medivation Inc. saying it would try to remove and replace members of the U.S. biotech firm’s board if it didn't engage in takeover talks.

Medivation Reiterates Rejection of Sanofi's Substantially Inadequate Proposal

5/5/2016 05:17 pm

(Medivation) May 5, 2016 - Medivation, Inc. today reiterated its rejection of Sanofi's substantially inadequate proposal to acquire the Company for $52.50 per share in cash, following the receipt of a letter from Sanofi.

Sanofi Says Sees 'Strong Strategic' Fit With Medivation

5/4/2016 04:45 pm

(Reuters) May 4, 2016 - Sanofi sees a strong strategic fit with U.S. cancer drug maker Medivation, the French pharmaceuticals company's chief executive said on Wednesday after recently approaching the company about a tie-up.

Medivation Rejects Takeover Bid From Sanofi

4/29/2016 04:17 pm

(New York Times/DealBook) Apr 29, 2016 - Medivation, which makes drugs for prostate cancer, has a message for the French drug company Sanofi: The $9.3 billion cash takeover offer was not good enough.

Cholesterol Levels, Not Statins, Influence Colorectal Cancer Risk, Penn Study Suggests

4/27/2016 11:04 am

(Penn Medicine) Apr 26, 2016 - Long-term use of the cholesterol-lowering drugs known as statins does not appear to decrease a patient's risk of colorectal cancer, suggests a new, large case-control study from Penn Medicine researchers published this week in PLOS Medicine.

Merck Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for KEYTRUDA® (pembrolizumab) in Classical Hodgkin Lymphoma (cHL)

4/18/2016 11:03 am

(Morningstar) Apr 18, 2016 - Fourth Designation for KEYTRUDA follows breakthrough status in advanced melanoma, non-small cell lung cancer, and colorectal cancer.

Perspective: Finding Value in Unexpected Places — Fixing the Medicare Physician Fee Schedule

4/7/2016 11:05 am

(NEJM) Apr 7, 2016 - "Moving from volume to value" is health care reform's latest mantra. Policymakers hope to replace fee-for-service systems with value-based approaches that reward improved outcomes achieved at lower cost. Ground zero in these efforts is the Medicare Physician Fee Schedule (MPFS).

Medicare Officials Halt Proposal to Penalize Doctors for Some Prostate Cancer-Screening Tests

3/28/2016 07:03 am

(Wall Street Journal) Mar 24, 2016 - Medicare officials said they have temporarily abandoned a proposed measure that would have penalized doctors for ordering “non-recommended” prostate-specific antigen tests to screen for prostate cancer, citing a wave of negative comments.

Longer Surgical Interval Shortens RFS When Residual Melanoma Is Present

3/21/2016 11:02 am

(Healio) Mar 18, 2016 - Longer surgical interval following initial biopsy may worsen RFS outcomes in patients with residual melanoma, according to a retrospective review presented at HemOnc Today Melanoma and Cutaneous Malignancies.

Marijuana May Help Cancer Patients, But Questions Remain

3/18/2016 10:00 am

(LiveScience) Mar 17, 2016 - Marijuana could potentially help cancer patients who have nausea or pain, and could possibly even be used as a treatment for certain cancers, but much more research is needed before any of these uses could be recommended, a new review article said.

Epizyme Lays Out Plans To Have Its Cancer Drug Approved as Soon as 2018

3/9/2016 12:03 pm

(Boston Business Journal/BioFlash blog) Mar 9, 2016 - Investors are taking a wait-and-see approach this morning after Cambridge biotech Epizyme laid out a grand vision to get its lead cancer drug approved, in the best case scenario, in a little over two years.

AstraZeneca's $4 Billion Acerta Deal Endorsed by Orphan Drug Status

2/25/2016 07:00 am

(Reuters) Feb 25, 2016 - AstraZeneca's bold move to buy 55 percent of privately held biotech firm Acerta Pharma for $4 billion in December has been vindicated, at least in part, by the award of special "orphan" status to the key experimental drug involved.

Why Donald Trump Would Have The Same Problems As Democrats On Medicare Drug Prices

1/27/2016 12:05 pm

(STAT) Jan 26, 2016 - Donald Trump stunned the health care world Monday night with his call for Medicare to negotiate drug prices — an idea that’s straight out of Hillary Clinton’s and Bernie Sanders playbooks, and one that other Republicans won’t touch.

A Pen-Sized Microscope Could Spot Cancer in Your Doctor's Office

1/26/2016 11:02 am

(Gizmodo) Jan 26, 2016 - The process of identifying cancer—from taking a sample of a tumor to getting the results back from a laboratory—can be long-winded. When there isn’t time for all that, this new hand-held microscope could help doctors identify cancer cells in just a few moments.

Zika Virus Set To Spread Across Americas, Spurring Vaccine Hunt

1/25/2016 11:04 am

(Reuters) Jan 25, 2016 - The mosquito-borne Zika virus, which has been linked to brain damage in thousands of babies in Brazil, is likely to spread to all countries in the Americas except for Canada and Chile, the World Health Organization said on Monday.

Janssen Voluntarily Suspends FAAH Inhibitor Phase 2 Trials In Wake Of Bial Tragedy

1/20/2016 12:01 pm

(Forbes) Jan 20, 2016 - While their drug has shown no adverse reactions in Phase 1 studies or ongoing Phase 2 trials to date, Janssen discontinues FAAH inhibitor dosing in two trials until more is known about the Bial drug trial tragedy in Rennes, France.

Mantle Cell Lymphoma Responds Well to Imbruvica

8/11/2015 11:04 am

(MedPage Today/The Gupta Guide) Aug 10, 2015 - Ibrutinib (Imbruvica), an oral inhibitor of Bruton tyrosine kinase, produced rapid and durable responses in heavily treated patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) -- now followed for a median of 26.7 months -- according to an updated report of the safety and efficacy of an open-label phase II registration trial.

Pediatric Brain Tumors Can be Classified Noninvasively at Diagnosis

8/10/2015 11:04 am

(CHLA) Aug 7, 2015 - Medulloblastoma, the most commonly occurring malignant brain tumor in children, can be classified into four subgroups—each with a different risk profile requiring subgroup-specific therapy.

Scientists Find Promising Target for Better Pain Drugs

8/6/2015 11:01 am

(MSKCC/On Cancer blog) Aug 6, 2015 - Memorial Sloan Kettering scientists have discovered how new analgesic medications work without the downsides of traditional opioid painkillers.

Bayer HealthCare Enters Into Collaboration With Sprint Bioscience On Tumor Metabolism Program

7/28/2015 12:00 pm

(Bayer) July 28, 2015 – Bayer HealthCare and the Swedish company Sprint Bioscience AB have entered into a collaboration and license agreement for the research, development, and commercialization of oncological drug candidates.

AbbVie, Bristol-Myers Get FDA Nod For Hep C Treatments

7/27/2015 12:01 pm

(Reuters) July 24, 2015 - The U.S. Food and Drug Administration on Friday approved two treatments for less common forms of hepatitis C virus (HCV) infections.

Some Serious Drug Side Effects Not Told To FDA Within 15 Days

7/27/2015 12:00 pm

(Reuters Health) July 27, 2015 - Companies fail to report roughly one in 10 serious and unexpected medication side effects to the U.S. Food and Drug Administration (FDA) within a 15-day window specified by federal regulations to protect patient safety, a study finds.

Horizon Pharma plc Announces Collaboration With Fox Chase Cancer Center to Study ACTIMMUNE(R) (interferon gamma-1b) in Combination With PD-1/PD-L1 Inhibitors in Various Forms of Cancer

7/27/2015 11:05 am

(CNN Money) July 27, 2015 - Horizon Pharma plc today announced a collaboration with Fox Chase Cancer Center to study ACTIMMUNE (interferon gamma-1b) in combination with PD-1/PD-L1 inhibitors in various forms of cancer including advanced urothelial carcinoma (bladder cancer) and renal cell carcinoma.